Gemcitabine nab-PaclitaxelLenvatinibTislelizumab

Phase 2Monoclonal antibody

Gemcitabine nab-PaclitaxelLenvatinibTislelizumab is one of 21 small molecule programs targeting Unresectable. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

UnresectableEnrolling by invitation

UnresectablePhase 2

Enrolling by invitation

Competition

Competitive Landscape

21 competitors in Unresectable

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

8 2

Tecentriq

Roche

Phase 3

3 3

Lenvima

Eisai

Phase 2

3 4

Vitrakvi

Bayer

Phase 2

1 5

Tagrisso

AstraZeneca

Phase 2

1 6

Tafinlar

Novartis

Phase 2

1 7

Camptosar

Pfizer

Phase 2

1 8

Zegfrovy

DDizal Pharmaceuticals

Phase 2

1 9

Xalkori

PPrism Pharmaceuticals

Phase 2

1 10

Ensacove

XXcovery Holdings, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Unresectable1 trial

Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)

Enrolling by invitation·WWei Gong·Phase 2·NCT06963060·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Gemcitabine nab-PaclitaxelLenvatinibTislelizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gemcitabine nab-PaclitaxelLenvatinibTislelizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gemcitabine nab-PaclitaxelLenvatinibTislelizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Wei Gong company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: WWei Gong

Gemcitabine nab-PaclitaxelLenvatinibTislelizumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Unresectable1 trial

References

Drug Info

Quick Facts

Related News